GlassScriptPhysician profile
Rameen M Miarrostami
NPI 1497734743
$2,535.07
in general payments reported to CMS, 2019-2025
16 companies · $763 in 2025
The $763 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.45 · 2021: $190 · 2022: $322 · 2023: $396 · 2024: $835 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,915 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,914.83 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,250.55 | 2019-2025 | Trelegy Ellipta, Nucala |
| Alkermes, INC. | $352.26 | 2022-2023 | Lybalvi |
| Astrazeneca Pharmaceuticals LP | $151.74 | 2019-2023 | Tezspire |
| Boston Scientific Corporation | $150.00 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $116.99 | 2024-2025 | Zoryve |
| Abbvie INC. | $99.99 | 2021 | |
| Pfizer INC. | $82.40 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $78.99 | 2024 | Uptravi, Opsumit |
| Curonix LLC | $78.66 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Electromed, INC. | $33.65 | 2025 | Smartvest |
| Novartis Pharmaceuticals Corporation | $31.81 | 2023 | |
| Philips North America LLC | $25.69 | 2025 | Vest Therapy Und |
| Mallinckrodt Hospital Products INC. | $24.86 | 2025 | Acthar |
| Abbott Laboratories | $21.46 | 2024 | Freestyle Libre 2 |
| Insmed, INC. | $18.94 | 2025 | Arikayce |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $17.08 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rameen Miarrostami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.